- Home
- LPCN vs MBRX Comparison
LPCN vs MBRX Comparison
Compare LPCN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- MBRX
- Stock Information
- Founded
- LPCN 1997
- MBRX 2015
- Country
- LPCN United States
- MBRX United States
- Employees
- LPCN N/A
- MBRX N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- MBRX Health Care
- Exchange
- LPCN Nasdaq
- MBRX Nasdaq
- Market Cap
- LPCN 16.1M
- MBRX 17.1M
- IPO Year
- LPCN N/A
- MBRX 2016
- Fundamental
- Price
- LPCN $2.99
- MBRX $0.41
- Analyst Decision
- LPCN Strong Buy
- MBRX Strong Buy
- Analyst Count
- LPCN 2
- MBRX 4
- Target Price
- LPCN $9.00
- MBRX $5.00
- AVG Volume (30 Days)
- LPCN 16.6K
- MBRX 4.8M
- Earning Date
- LPCN 11-06-2025
- MBRX 11-07-2025
- Dividend Yield
- LPCN N/A
- MBRX N/A
- EPS Growth
- LPCN N/A
- MBRX N/A
- EPS
- LPCN N/A
- MBRX N/A
- Revenue
- LPCN $4,208,119.00
- MBRX N/A
- Revenue This Year
- LPCN N/A
- MBRX N/A
- Revenue Next Year
- LPCN N/A
- MBRX N/A
- P/E Ratio
- LPCN N/A
- MBRX N/A
- Revenue Growth
- LPCN N/A
- MBRX N/A
- 52 Week Low
- LPCN $2.68
- MBRX $0.25
- 52 Week High
- LPCN $6.17
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- LPCN 50.61
- MBRX 42.61
- Support Level
- LPCN $2.85
- MBRX $0.36
- Resistance Level
- LPCN $3.08
- MBRX $0.42
- Average True Range (ATR)
- LPCN 0.09
- MBRX 0.03
- MACD
- LPCN 0.01
- MBRX 0.01
- Stochastic Oscillator
- LPCN 59.83
- MBRX 87.89
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.